Flashcards · Module 24
💊 High-Risk Medications & Toxicology
4 of 4 cards published · read by the site’s author on 18 November 2026
Serotonin Syndrome vs. Neuroleptic Malignant Syndrome (NMS): Clonus vs. Lead-Pipe Rigidity
Needs clinical review
Two Medication Emergencies Compared:
| Feature | Serotonin Syndrome (SS) ⚡ | Neuroleptic Malignant Syndrome (NMS) 🗿 |
|---|---|---|
| Trigger Drugs | Serotonergic combinations: SSRI/SNRI + Tramadol, Linezolid, Triptans, Fentanyl, St. John's Wort | Dopamine D2 antagonists: Haloperidol, Olanzapine, Promethazine, Metoclopramide; or abrupt Levodopa stop |
| Onset | RAPID (within hours) of starting/increasing dose | GRADUAL (days to weeks) |
| Neuromuscular | • HYPERREFLEXIA • CLONUS (Spontaneous, inducible, or ocular clonus) 🚨 • Tremor & shivering (legs > arms) | • "LEAD-PIPE" RIGIDITY (extreme stiffness) • HYPOREFLEXIA • Bradykinesia |
| Pupils & Gut | Mydriasis (dilated pupils); hyperactive bowel sounds / diarrhea | Normal pupils; normal or decreased bowel sounds |
| Fever & Labs | Mild fever to severe hyperthermia (>40°C in moderate–severe cases); CK and leukocytosis less prominent than in NMS | High-grade Hyperthermia (frequently >40°C); elevated Creatine Kinase (CK usually >1,000 U/L); leukocytosis |
| Antidote | Cyproheptadine (serotonin antagonist) + benzos | Dantrolene (muscle relaxant) / Bromocriptine (dopamine agonist) |
Sources checked (6) · 18 November 2026
- A Narrative Review on Toxidromes in the Psychiatric Population: Implications for Overdose Prevention (2025)
- Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions (2019)
- Acute Febrile Encephalopathy with Rigidity (2025)
- Precipitants and clinical features of serotonin syndrome: a systematic review with patient-level analysis of published case reports and series (2026)
- Anesthetic implications of psychotropic medications: a narrative review (2025)
- The Genetic Foundations of Serotonin Syndrome, Neuroleptic Malignant Syndrome, and Malignant Hyperthermia: Is There a Genetic Association Between These Disorders? (2020)
Note: In Parkinson disease, stopping levodopa produces a clinically similar NMS-like state now commonly termed parkinsonism-hyperpyrexia syndrome. (Acute Febrile Encephalopathy with Rigidity (2025))
Note: In NMS, pupils are usually normal (though mydriasis is occasionally reported) and bowel sounds are normal or hypoactive. (Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions (2019))
Note: Elevated CK and leukocytosis can occur in serotonin syndrome, though they tend to be less prominent than in NMS. (Acute Febrile Encephalopathy with Rigidity (2025))
Note: Evidence for specific antidotes such as dantrolene and bromocriptine is based on case series and they are typically reserved for moderate or severe NMS alongside drug cessation and supportive care. (Acute Febrile Encephalopathy with Rigidity (2025))
Opioid-Induced Constipation (OIC) & PAMORAs: Why little or no tolerance develops
Needs clinical review
The Pharmacological Reality:
When patients take opioids for chronic pain or cancer, side effects such as sedation and nausea typically improve with continued use. But:
LITTLE OR NO TOLERANCE DEVELOPS TO CONSTIPATION.
Opioids acting on mu receptors in the gut wall suppress intestinal motility and reduce fluid secretion into the gut.
The Golden Prescribing Rule:
Patients started on long-term standing opioids should receive a prophylactic laxative bowel regimen (osmotic and/or stimulant) from the outset:
Senna (or Bisacodyl) + PEG 3350 (Miralax) daily.
❌ Do NOT give bulk-forming fiber (Psyllium) — fiber-based bulking agents may worsen bloating and are generally contraindicated in OIC.
What are PAMORAs?
When standard laxatives fail for Opioid-Induced Constipation, use a Peripherally Acting Mu-Opioid Receptor Antagonist (PAMORA):
Methylnaltrexone (SubQ injection)
Naloxegol or Naldemedine (Oral daily)
How they work: methylnaltrexone, a quaternary amine, crosses the blood-brain barrier poorly, so it blocks gut mu-opioid receptors (subcutaneously, often within 4 hours) without reversing central analgesia (monitor for withdrawal if the barrier is disrupted).
Sources checked (5) · 18 November 2026
- Opioid-Induced Constipation: Mechanistic Insights, Experimental Models, and Future Perspectives (2026)
- Opioid-induced constipation in internal medicine: recognition and management pathways (2025)
- DailyMed - RELISTOR- methylnaltrexone bromide tablet RELISTOR- methylnaltrexone bromide injection, solution
- DailyMed - MOVANTIK- naloxegol oxalate tablet, film coated
- DailyMed - SYMPROIC- naldemedine tablet
Note: Polyethylene glycol (PEG 3350) is an osmotic laxative that retains water in the lumen; stimulant laxatives (senna, bisacodyl) can be used as alternatives or added when PEG alone is insufficient. (Management of constipation: A narrative review of evolving strategies and methodological challenges (2026))
Note: Methylnaltrexone is available as both a subcutaneous injection and an oral tablet formulation. (DailyMed - RELISTOR- methylnaltrexone bromide tablet RELISTOR- methylnaltrexone bromide injection, solution)
Note: PAMORAs carry a risk of gastrointestinal perforation and are contraindicated in patients with known or suspected GI obstruction; patients with blood-brain barrier disruptions should be monitored for opioid withdrawal. (DailyMed - SYMPROIC- naldemedine tablet)
Digoxin Toxicity in the Aging Kidney: Yellow halos, nausea, and narrow windows
Needs clinical review
Why Older Adults Get Poisoned:
Shrinking Muscle Mass: age-related loss of lean muscle lowers digoxin's volume of distribution, so doses need careful selection and monitoring.
Declining GFR: Digoxin is eliminated mainly by the kidneys (50–70% excreted unchanged in urine, proportional to creatinine clearance). Half-life is 1.5–2 days with normal renal function and prolongs to 3.5–5 days in anuric patients.
Loop Diuretics: Furosemide causes hypokalemia and hypomagnesemia—and low potassium and magnesium predispose to digoxin toxicity, which can occur even at "normal" serum levels!
Symptoms of Digoxin Toxicity:
🤢 Gastrointestinal (Early): Anorexia, nausea, vomiting, unexplained weight loss.
🧠 Neurologic: Acute confusion, delirium, fatigue, headache.
👁️ Visual (Classic): Xanthopsia (yellow-green halos around lights, altered color perception).
🫀 Cardiac: Almost any arrhythmia! (PVC bigeminy, junctional escape rhythms, high-grade AV block, bidirectional VT).
The Modern Geriatric Window & Antidote:
In heart failure, the favoured target range is 0.5 to 0.8 ng/mL. Levels ≥1.2 ng/mL are associated with higher mortality and toxicity risk!
Antidote: Digoxin-Specific Fab Fragments (DigiFab) indicated for life-threatening arrhythmias or hyperkalemia (>5.5 mEq/L in adults per FDA label; Digibind is unavailable in North America).
Sources checked (5) · 18 November 2026
- DailyMed - DIGOXIN injection
- DailyMed - LASIX ONYU- furosemide injection
- Diagnosis and practical management of digoxin toxicity: a narrative review and consensus (2023)
- Association of serum digoxin concentration and outcomes in patients with heart failure (2003)
- DailyMed - DIGIFAB- ovine digoxin immune fab injection, powder, lyophilized, for solution
Note: In chronic toxicity, hypokalemia confers increased susceptibility to dysrhythmias at lower cardiac glycoside concentrations. (Two cases of cardiac glycoside poisoning from accidental foxglove ingestion (2016))
Note: Color vision aberration with a predominance of yellow-green is the most frequent visual symptom on the FDA digoxin label. (DailyMed - DIGOXIN injection)
Note: The EHRA/ESC consensus advises keeping serum digoxin levels <1 ng/mL and warns that levels >1.2 ng/mL may increase toxicity risk without additional benefit. (Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology (2025))
Note: A European consensus lists serum potassium >6.5 mmol/L as an immediate indication for digoxin immune Fab, while noting that mild-to-moderate hyperkalaemia (5.5–6.5 mmol/L) should resolve with Fab treatment. (Diagnosis and practical management of digoxin toxicity: a narrative review and consensus (2023))
Emergency Anticoagulation Reversal: Stopping the bleed from Warfarin, Dabigatran, and Factor Xa inhibitors
Needs clinical review
The Trauma Scenario:
An 80-year-old on blood thinners falls down the stairs and has an acute subdural hematoma on head CT. You need to reverse anticoagulation NOW. What is the specific antidote?
The Reversal Matrix:
| Anticoagulant Drug | Specific Reversal Agent | How It Works & Speed |
|---|---|---|
| Warfarin (Vitamin K antagonist) | 4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra) + IV Vitamin K (given at the same time) | 4F-PCC supplies factors II, VII, IX, and X rapidly (decreases INR to ≤1.3 within 30 minutes in most patients); Vitamin K maintains factor levels once 4F-PCC effects diminish |
| Dabigatran (Pradaxa) (Direct thrombin inhibitor) | Idarucizumab (Praxbind) (5 g IV) | Humanized monoclonal antibody fragment that binds free dabigatran with 350-fold higher affinity than thrombin (immediate reversal!) |
| Factor Xa Inhibitors (Apixaban / Rivaroxaban) | Andexanet alfa (Andexxa) (or off-label 4F-PCC 25–50 U/kg — now the primary option where andexanet alfa is no longer commercially available) | Recombinant decoy Factor Xa protein that binds and neutralizes circulating Xa inhibitors |
Why NOT Fresh Frozen Plasma (FFP) for Warfarin?
FFP requires ABO matching and thawing delays, delivers a much larger fluid volume (mean ~819 mL vs ~90 mL for 4F-PCC in the Kcentra RCT, raising fluid overload and pulmonary complication risk), and infuses and reverses INR much more slowly than 4F-PCC (mean 169 min vs 24 min).
Sources checked (6) · 18 November 2026
- Anticoagulants, Their Laboratory Monitoring, and Reversal (2026)
- DailyMed - ANDEXXA- andexanet alfa injection, powder, lyophilized, for solution
- DailyMed - KCENTRA- prothrombin, coagulation factor vii human, coagulation factor ix human, coagulation factor x human, protein c, protein s human, and water kit
- DailyMed - PRAXBIND- idarucizumab injection
- Safety and efficacy of idarucizumab-assisted thrombolysis in dabigatran-related acute ischemic stroke: a systematic review and single-arm meta-analysis (2026)
- Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures (2026)
Note: Intravenous vitamin K (up to 10 mg depending on INR) lowers INR within 4–6 hours and carries a boxed warning for rare severe hypersensitivity reactions; 4F-PCC is the gold standard for emergent warfarin reversal. (Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation (2026))
Note: In clinical pharmacology studies, unbound dabigatran fell below the lower limit of quantification immediately after 5 g idarucizumab. (DailyMed - PRAXBIND- idarucizumab injection)
Note: Andexanet alfa carries a US boxed warning for thromboembolic risks, ischemic risks, cardiac arrest, and sudden deaths. (DailyMed - ANDEXXA- andexanet alfa injection, powder, lyophilized, for solution)
Note: FFP also entails ABO matching and thawing delays and has been associated with dose-dependent pulmonary complications in 20% of patients when more than 3 units are used. (Anticoagulants, Their Laboratory Monitoring, and Reversal (2026))